In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. The company’s shares closed yesterday at ...

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...

GlaxoSmithKline (GSK) has firmly acquired the number one position in the Egyptian pharmaceutical market since 2009 and is likely to maintain the grip at least until the end of 2011. GSK’s ...

GlaxoSmithKline is under pressure from shareholders ... pay package compared with her predecessor. Previously head of GSK’s consumer health division, Walmsley joined the company in 2010 after ...

ASHG welcomed eight 2024–2026 Human Genetics Scholars who are recognized for their accomplishments and commitment to fostering DEI in human genetics and genomics.

GlaxoSmithKline, the London-based pharmaceutical giant with a substantial presence in Montgomery County and Philadelphia, announced a landmark investment ...

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

The continent is being drenched in an avalanche of medical disinformation with the aim of undermining western influence ...

Teva Pharmaceutical Industries Ltd. ADR-2.23% $19.91B ...

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GSK plc, a worldwide healthcare organisation driven by research that aims to bring talent, science, and technology together to prevent ...